Q-omics provides the consensus-scored SDHCP1 profile across patient tissues and cancer cell-line models. SDHCP1 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, SDHCP1 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, SDHCP1 RNA expression shows 10,005 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight READ, BRCA, and LSCC as cancer lineages where SDHCP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SDHCP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SDHCP1 survival associations across molecular data types. SDHCP1 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SDHCP1 RNA expression–survival associations across cancer types. High SDHCP1 expression shows unfavorable associations in READ, UVM, KIRC, ACC, STAD and SARC. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for SDHCP1 RNA expression.
This table summarizes SDHCP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SDHCP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SDHCP1 shows higher tumor expression in BRCA and LUAD. The BRCA box plot shows higher SDHCP1 RNA expression in tumor versus normal tissue (log2 FC = +0.039, t-test p = .028).
This table shows molecular features associated with SDHCP1 in patient tissues and cancer cell lines. In patient samples, SDHCP1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
